Real-time enrollment status for this relapsed or refractory hematologic malignancies clinical trial
Current Status
Recruiting
Checked: July 17, 2026 at 5:17 AM UTC
| NCT Number | NCT03838926 |
| Recruiting Status | Recruiting |
| Condition | Relapsed or Refractory Hematologic Malignancies |
| Phase | PHASE1 |
| Target Enrollment | 42 participants |
| Active Locations | 4 sites in the US |
| Sponsor | Vanda Pharmaceuticals |
| Last Updated on CT.gov | March 16, 2026 (Mar 16, 2026) |
As of July 17, 2026: Clinical trial NCT03838926 is currently recruiting participants. This phase1 study for relapsed or refractory hematologic malignancies is actively seeking new participants at 4 locations across the United States. The study is sponsored by Vanda Pharmaceuticals. This status information is automatically verified from the official ClinicalTrials.gov registry.
Yes, NCT03838926 is actively recruiting participants as of July 17, 2026. You can check eligibility and apply through HelloStudys.
This trial is recruiting at 4 locations in the United States. View all available locations on the full study page.
Check your eligibility and express interest by completing the application form on the study page. A research coordinator will follow up to discuss next steps.
The official ClinicalTrials.gov record for NCT03838926 was last updated Mar 16, 2026 (March 16, 2026). HelloStudys verifies this status automatically.